This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Asnacios, A. Articles by Buscail, L. Search for Related Content PubMed PubMed Citation Articles by Asnacios, A. Articles by Buscail, L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                            What's this?

Indium-111–Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors

Amani Asnacios, Frédéric Courbon, Philippe Rochaix, Eric Bauvin, Valérie Cances-Lauwers, Christiane Susini, Stefan Schulz, Andrée Boneu, Rosine Guimbaud, Louis Buscail

From the Departments of Medical Oncology, Pathology, and Nuclear Medicine, Claudius Regaud Institute; Department of Epidemiology, School of Medicine, Toulouse-Purpan; Department of Gastroenterology and School of Medicine, Toulouse-Rangueil; Centre Hospitalier Universitaire Rangueil, Toulouse, France; and Department of Pharmacology, University of Wurzburg, Wurzburg, Germany

Corresponding author: Louis Buscail, MD, L’Institut National de la Santé et de la Recherche Médicale 858, I2MR, Centre Hospitalier Universitaire Rangueil, BP 84225-31432 Toulouse Cedex 04, France; e-mail: Louis.Buscail{at}toulouse.inserm.fr

Purpose Well-differentiated metastatic endocrine carcinomas are difficult to manage because of variable disease outcome. New prognostic factors are required. These tumors overexpress somatostatin receptors (sst), implying the use of somatostatin analogs for tumor localization by somatostatin receptor scintigraphy using indium-111–pentetreotide (¹¹¹In-pentetreotide) and for medical treatment. The aim of the present study was to evaluate the correlation between ¹¹¹In-pentetreotide scintigraphy, sst receptor expression, and prognosis.

Patients and Methods Between 1994 and 2002, 48 consecutive patients with well-differentiated endocrine carcinomas and a negative ¹¹¹In-pentetreotide scintigraphy were retrospectively paired according to sex, age, and tumor localization with 50 patients with well-differentiated endocrine carcinomas and a positive tracer uptake at ¹¹¹In-pentetreotide scintigraphy. Overall survival and expression of sst1 to sst5 receptors by immunohistochemistry were assessed.

Results The lack of tracer uptake at the ¹¹¹In-pentetreotide scintigraphy seemed to be a poor prognostic factor (P = .007) for overall survival by Kaplan-Meier test and in multivariate analysis; age and absence of clinical secretory syndrome also seemed to be poor prognostic factors. The tracer uptake (positive ¹¹¹In-pentetreotide scintigraphy) correlated with the tumor expression of somatostatin receptor sst2 (P < .001) but not with that of sst1, sst3, sst4, or sst5. In a bivariate analysis, lack of sst2 expression also significantly correlated with poor prognosis.

Conclusion We demonstrate the prognostic value of ¹¹¹In-pentetreotide scintigraphy in well-differentiated malignant endocrine tumors. In these tumors, sst2 somatostatin receptor expression correlates with both tracer uptake and a better prognosis.

Supported by grants from Groupe de Recherche de l’Institut Claudius Régaud, Association pour la Recherche Contre le Cancer, and L’Institut National de la Santé et de la Recherche Médicale.

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Lesche, D. Lehmann, F. Nagel, H. A. Schmid, and S. Schulz Differential Effects of Octreotide and Pasireotide on Somatostatin Receptor Internalization and Trafficking in Vitro J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 654 - 661. [Abstract] [Full Text] [PDF]

				T. Fischer, C. Doll, S. Jacobs, A. Kolodziej, R. Stumm, and S. Schulz Reassessment of sst2 Somatostatin Receptor Expression in Human Normal and Neoplastic Tissues Using the Novel Rabbit Monoclonal Antibody UMB-1 J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4519 - 4524. [Abstract] [Full Text] [PDF]